• LEARN MORE ABOUT KEYNOTE 695
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact
OncoSec Medical Incorporated
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

OncoSec Receives $7 Million Investment From Alpha Holdings At $1.50 Per Share

Dec 10, 2018 8:30am EST

OncoSec Presents New Data During Oral Presentation At Melanoma Bridge Demonstrating Intratumoral Monotherapy TAVO™ Induces Abscopal Responses In Metastatic Melanoma Patients

Nov 29, 2018 8:00am EST

OncoSec to Present at Piper Jaffray 30th Annual Healthcare Conference

Nov 20, 2018 8:00am EST

OncoSec To Present Data in Late-Stage Triple Negative Breast Cancer (TNBC) at the 2018 San Antonio Breast Cancer Symposium®

Nov 13, 2018 8:00am EST

OncoSec Appoints Robert Ward to its Board of Directors

Nov 08, 2018 8:00am EST

OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

Nov 07, 2018 8:00am EST

OncoSec Reports Preliminary Data from KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial of TAVO™ in Combination with KEYTRUDA® for Metastatic Melanoma at Society for Immunotherapy of Cancer's 33rd Annual Meeting

Nov 06, 2018 8:00am EST

OncoSec to Host Conference Call to Review Preliminary KEYNOTE-695 Data

Nov 05, 2018 8:00am EST

OncoSec Announces Preliminary Data from KEYNOTE-695 Study Accepted for Late-Breaking Presentation at SITC Annual Meeting

Nov 02, 2018 8:00am EDT

OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer

Oct 29, 2018 8:00am EDT
RSS
  • Prev
    • 1...
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • ...46
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    logo

    Sign Up for our mailing list to stay current on all of our exciting new research and developments.

    Get Email Alerts
    OncoSec’s investigational products have not been approved or cleared by the FDA.

    Links

    • About
    • Pipeline
    • Technology
    • Partnering
    • Patients
    • Media
    • Investors
    • Contact
    • KEYNOTE 695 CLINICAL TRIAL

    Contact

    New Jersey Headquarters
    24 N. Main St
    Pennington, NJ 08534

    R&D Laboratories
    3565 General Atomics Court #100
    San Diego, CA 92121

    p | 855.662.6732
    f | 858.430.3832

    Investors@OncoSec.com


    © 2023 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E.